Production (Stage)
CNS Pharmaceuticals, Inc.
CNSP
$0.811
$0.00370.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.59M | 5.61M | 5.02M | 4.76M | 4.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.69M | 14.90M | 17.08M | 15.99M | 17.48M |
| Operating Income | -15.69M | -14.90M | -17.08M | -15.99M | -17.48M |
| Income Before Tax | -15.61M | -14.86M | -17.06M | -15.97M | -17.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.61 | -14.86 | -17.06 | -15.97 | -17.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.61M | -14.86M | -17.06M | -15.97M | -17.46M |
| EBIT | -15.69M | -14.90M | -17.08M | -15.99M | -17.48M |
| EBITDA | -15.69M | -14.90M | -17.08M | -15.98M | -17.48M |
| EPS Basic | -17.17 | -15.59 | -12.64 | -- | -- |
| Normalized Basic EPS | -10.73 | -9.75 | -7.90 | -- | -- |
| EPS Diluted | -17.18 | -15.60 | -12.64 | -- | -- |
| Normalized Diluted EPS | -10.73 | -9.75 | -7.90 | -- | -- |
| Average Basic Shares Outstanding | 4.24M | 1.52M | 443.60K | -- | -- |
| Average Diluted Shares Outstanding | 4.24M | 1.52M | 443.60K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |